A new proposal in JAMA Internal Medicine suggests that the FDA should create an approval pathway for medical AI tools that parallels how physicians are trained and licensed.

Pooled patients treated with TTI-101 demonstrated a 9.4% decrease from baseline in fibrosis score at week 12, compared to a 2.4% decrease for the ...

Traditional trial start-up workflows often follow a sequential path, from feasibility to contracting, then regulatory ...

ASN Kidney Week, held in November, featured leading-edge science in kidney care, with evidence supporting new drugs to treat immunoglobulin A nephropathy, address chronic kidney disease in specific ...

Cumulus Neuroscience, a leading innovator in brain health technology for clinical trials, today announced the publication of ...

CMPS has benefited from positive phase 3 trial results and positive political developments since my last article. Click here ...

Radiopharmaceutical therapy (RPT) offers molecular-targeted treatment strategies and presents an ideal model for advancing ...

Final results from the phase 3 CASSANDRA trial presented at the 2025 ASCO Meeting show that the neoadjuvant chemotherapy ...

When a baby smiles at you, it's almost impossible not to smile back. This spontaneous reaction to a facial expression is part ...

The Food and Drug Administration (FDA) updated its guidance on Tuesday to allow more wearables to fall into a general ...

The cell and gene therapy market is at a pivotal point, with a surge in approvals and a maturing pipeline. While oncology ...

Polyrizon Ltd. Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions today announced positive results from ...